Regeneron Pharmaceuticals, Inc. (0R2M)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 811.46 |
|---|---|
| 52-week range | 576.21 – 870.00 |
| Return, 1 month / 3 months | +3.0% / +20.9% |
| Return, 1 year / 3 years | +39.6% / +6.1% |
| Trend | Uptrend |
| RSI (14) | 59 |
| Volatility (1 year) | 31.6% |
| Worst drawdown (1 year) | -26.0% |
| Average daily value traded | 0.57M USD |
| Dividend yield | 0.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Regeneron Pharmaceuticals is a biotechnology company based in Tarrytown, New York, that discovers and makes prescription medicines. Its products include treatments for serious eye diseases such as macular degeneration and diabetic eye conditions, an injectable medicine for eczema, asthma and other allergic conditions developed with a partner, and a cancer immunotherapy for certain skin and lung cancers. It also runs a large research effort in antibody technologies and genetics, serving patients through doctors and health systems in markets around the world.
The shares are listed on the London Stock Exchange in UK under the code 0R2M, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Regeneron Pharmaceuticals, Inc. (0R2M) trades on the London Stock Exchange in UK. It last closed at USD 811.46 on 27 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 1,221 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 39.6% and over the last three months it rose 20.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 10.4% | ||
| From 52-week high | -4.7% | ||
| Momentum | 79 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 20.9% | ||
| 6-month return | 9.3% | ||
| 12-month return, skipping the last month | 35.5% | ||
| Stability (higher is calmer) | 58 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.0% | ||
| Liquidity | 47 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.57M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 4 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.5% | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.9% |
|---|---|
| 1 month | +3.0% |
| 3 months | +20.9% |
| 6 months | +9.3% |
| 1 year | +39.6% |
| 3 years | +6.1% |
| 5 years | +39.1% |
Signals
| 50-day / 200-day average | 792.58 / 735.29 |
|---|---|
| Golden / death cross (60 days) | Golden, 38 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 30.24 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Aug 2026 | USD 0.9400 |
| 20 May 2026 | USD 0.9400 |
| 20 Feb 2026 | USD 0.9400 |
| 20 Nov 2025 | USD 0.8800 |
| 18 Aug 2025 | USD 0.8800 |
| 20 May 2025 | USD 0.8800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.